Article info

Original research
Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer

Authors

  • Peixin Chen Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, ChinaTongji University, No 1239 Siping Road, Shanghai 200433, China PubMed articlesGoogle scholar articles
  • Lishu Zhao Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, ChinaTongji University, No 1239 Siping Road, Shanghai 200433, ChinaDepartment of Oncology, the Second Xiangya Hospital, Central South University, Changsha 410011, China PubMed articlesGoogle scholar articles
  • Hao Wang Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, ChinaTongji University, No 1239 Siping Road, Shanghai 200433, China PubMed articlesGoogle scholar articles
  • Liping Zhang Department of Pathology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, China PubMed articlesGoogle scholar articles
  • Wei Zhang Department of Pathology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, China PubMed articlesGoogle scholar articles
  • Jun Zhu Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, ChinaTongji University, No 1239 Siping Road, Shanghai 200433, China PubMed articlesGoogle scholar articles
  • Jia Yu Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, China PubMed articlesGoogle scholar articles
  • Sha Zhao Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, China PubMed articlesGoogle scholar articles
  • Wei Li Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, China PubMed articlesGoogle scholar articles
  • Chenglong Sun Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, ChinaAnhui No.2 Provincial People’s Hospital, Hefei, China PubMed articlesGoogle scholar articles
  • Chunyan Wu Department of Pathology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, China PubMed articlesGoogle scholar articles
  • Yayi He Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, ChinaTongji University, No 1239 Siping Road, Shanghai 200433, China PubMed articlesGoogle scholar articles
  • Caicun Zhou Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, School of Medicine, Tongji University, Shanghai 200092, ChinaTongji University, No 1239 Siping Road, Shanghai 200433, China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Yayi He; 2250601{at}qq.com
View Full Text

Citation

Chen P, Zhao L, Wang H, et al
Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer

Publication history

  • Accepted June 17, 2021
  • First published August 6, 2021.
Online issue publication 
August 06, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.